Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy.

Waldmann, Thomas A; Chen, Jing

Waldmann, Thomas A; Chen, Jing.

Affiliation

Waldmann TA; Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892; email: tawald@helix.nih.gov.
Chen J; Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892; email: tawald@helix.nih.gov.

Annu Rev Immunol ; 35: 533-550, 2017 04 26.

Article in En | MEDLINE | ID: mdl-28182501

Subject(s)

Antibodies, Monoclonal/therapeutic use; Enzyme Inhibitors/therapeutic use; Immunotherapy/methods; Janus Kinases/metabolism; Lymphoma, T-Cell/immunology; STAT Transcription Factors/metabolism; Animals; Antineoplastic Agents/therapeutic use; Carcinogenesis; Cytokines/immunology; Cytokines/metabolism; Humans; Interleukin Receptor Common gamma Subunit/metabolism; Lymphoma, T-Cell/therapy; Receptors, Cytokine/antagonists & inhibitors; Signal Transduction

Key words

JAK/STAT; T cell lymphoma; Î³c cytokines

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, T-Cell / Enzyme Inhibitors / STAT Transcription Factors / Janus Kinases / Immunotherapy / Antibodies, Monoclonal Type of study: Etiology_studies Limits: Animals / Humans Language: En Journal: Annu Rev Immunol Year: 2017 Type: Article

Fulltext

XML

PubMed Links

Search on Google